


# theranica

New era in pain management


## Proven efficacy and favorable safety profile of Nerivio® for the acute treatment of migraine

Nerivio® is a novel remote neuromodulation device for the acute treatment of migraine. Peripheral nerves of the upper arm are stimulated to induce conditioned pain modulation (CPM)<sup>1</sup> – a descending endogenous analgesic mechanism in which a noxious stimulus in one part of the body inhibits pain in remote body region. A large prospective, randomized, double-blind, sham-controlled, multi-center study demonstrated that remote electrical neuromodulation (REN) is an effective acute treatment with a favorable tolerability profile.

Response at 2 hours post-treatment



Sustained response at 48 hours post-treatment



Remote electrical neuromodulation (REN) provides clinically meaningful relief of migraine pain and most bothersome symptom (MBS) compared to placebo

Pain relief and pain free responses were sustained 48 hours after treatment\*


\*Sustained pain relief/pain free is defined as having a headache response at 2 hours post-treatment, with no use of rescue medication and no return to baseline/relapse of headache pain within 48 hours

23 device-related adverse events during 773 treatments (2.7%)

9 of 252 participants (3.6%) reported device-related adverse events

All device-related adverse events were mild, did not require medical treatment and resolved shortly after treatment

There were no serious adverse events and no discontinuation due to adverse events



Proven efficacy



Well-tolerated

# Nerivio® offers a novel, non-pharmacological alternative for acute migraine treatment

Reference:

Nir R-R, Yarnitsky D. Conditioned pain modulation. Curr Opin Support Palliat Care 2015;9(2):131-137.

Nerivio® is indicated for acute treatment of migraine with or without aura in patients 18 years of age. It is a prescription use, self-administered device for use in the home environment at the onset of migraine headache or aura.

#### IMPORTANT SAFETY INFORMATION

Nerivio® should not be used by people with congestive heart failure, severe cardiac or cerebrovascular disease, or uncontrolled epilepsy. Nerivio® should not be used by anyone with active implantable medical devices (eg, pacemaker, hearing aid implant). It should only be applied on the upper arm over dry, healthy skin with normal physical sensation and without any metallic implants or in proximity to cancerous lesions. Nerivio® has not been evaluated in pregnancy or those under the age of 18. For full use instructions and safety information, please see the Nerivio® QuickStart Guide.

Further information: [www.theranica.com](http://www.theranica.com) Contact: [support@theranica.com](mailto:support@theranica.com)